Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Bruchfeld

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Pathogens (Basel, Switzerland)|December 31, 2025
Association of Antimicrobial Susceptibility with Treatment Response in <i>Mycobacterium avium complex</i> Pulmonary DiseaseXuejiao Luo, Yuhang Chen, Lina Davies Forsman, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 4, 2024
Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatmentSainan Wang, Lina Davies Forsman, Chunhua Xu, et al.
BMJ Open|April 14, 2025
Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO): a randomised, placebo-controlled, double-blind, phase II trialAnders Kjellberg, Adrian Hassler, Emil Boström, et al.
Tuberculosis (Edinburgh, Scotland)|April 5, 2011
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosisMorten Ruhwald, Jose Dominguez, Irene Latorre, et al.
Journal of Mass Spectrometry and Advances in the Clinical Lab|August 29, 2022
Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45]Johanna Kuhlin, Marieke G G Sturkenboom, Samiksha Ghimire, et al.
Clinical Mass Spectrometry (Del Mar, Calif.)|December 22, 2021
Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugsJohanna Kuhlin, Marieke G G Sturkenboom, Samiksha Ghimire, et al.
Journal of Clinical Microbiology|October 29, 2025
A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, IL-2, and TNF-secreting cells can improve accuracy and differentiation across the tuberculosis spectrumElin Folkesson, Fariba Foroogh, Linn Kleberg, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2018
Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic settingKatarina Niward, Lina Davies Forsman, Judith Bruchfeld, et al.
BMJ Open|November 2, 2022
Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trialAnders Kjellberg, Lina Abdel-Halim, Adrian Hassler, et al.
BMJ Open|October 6, 2018
Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort studyLina Davies Forsman, Katarina Niward, Yi Hu, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Pathogens (Basel, Switzerland)|December 31, 2025
Association of Antimicrobial Susceptibility with Treatment Response in <i>Mycobacterium avium complex</i> Pulmonary DiseaseXuejiao Luo, Yuhang Chen, Lina Davies Forsman, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 4, 2024
Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatmentSainan Wang, Lina Davies Forsman, Chunhua Xu, et al.
BMJ Open|April 14, 2025
Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO): a randomised, placebo-controlled, double-blind, phase II trialAnders Kjellberg, Adrian Hassler, Emil Boström, et al.
Tuberculosis (Edinburgh, Scotland)|April 5, 2011
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosisMorten Ruhwald, Jose Dominguez, Irene Latorre, et al.
Journal of Mass Spectrometry and Advances in the Clinical Lab|August 29, 2022
Corrigendum to "Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs" [Clin. Mass Spectrom. 14(Part A) (2019) 34-45]Johanna Kuhlin, Marieke G G Sturkenboom, Samiksha Ghimire, et al.
Clinical Mass Spectrometry (Del Mar, Calif.)|December 22, 2021
Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugsJohanna Kuhlin, Marieke G G Sturkenboom, Samiksha Ghimire, et al.
Journal of Clinical Microbiology|October 29, 2025
A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, IL-2, and TNF-secreting cells can improve accuracy and differentiation across the tuberculosis spectrumElin Folkesson, Fariba Foroogh, Linn Kleberg, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2018
Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic settingKatarina Niward, Lina Davies Forsman, Judith Bruchfeld, et al.
BMJ Open|November 2, 2022
Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trialAnders Kjellberg, Lina Abdel-Halim, Adrian Hassler, et al.
BMJ Open|October 6, 2018
Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort studyLina Davies Forsman, Katarina Niward, Yi Hu, et al.
Pageof 10